Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ISOPLEXIS CORPORATION
- Proposal award date
- 2017-06-15
- Contract end date
- 2017-12-15
- UEI
- FRM2JMLMGJK1
- Solicitation number
- PA16-302
- Topic code
- R
Research abstract
Autoimmune disease AD affects up to million Americans which costs approximately $
billion on health care annually and accounts for one of the leading causes of death in women T
cells and cytokine function play an important role in autoimmune diseases such as Type
Diabetes Multiple Sclerosis Rheumatoid Arthritis RA and Systemic Lupus Erythematosus
SLE The most successful auto immune therapies already target the factors secreting from or
binding to T cells e g TNF IL IL and IL Diagnosis of autoimmune diseases is typically
made post presentation of symptoms enabling earlier diagnosis through detecting the T cells that
drive disease progression pathogenic T cells could shift paradigms towards earlier and more
successful treatment IsoPlexis is developing a system to target and measure single T cells
integral to this early diagnosis In this Phase I project we will use SLE as a preliminary disease
with which to evaluate the strength of our technology SLE is an autoimmune disease mediated
by autoreactive antibodies yet a subset of T cells called follicular helper T Tfh cells when
dysregulated or pathogenic promote the induction of B cell autoantibody production Identifying
these rare disease causing T cells also present in circulation has been proposed as a critical
early diagnostic and a pressing need in the clinic However there are major challenges that need
to be addressed pathogenic circulating Tfh cells are present at low frequency in blood
these cells are highly heterogeneous with diverse combinations of effector cytokine functions
requiring single cell analysis and the range of cytokine functional groups that matters numbers
The IsoPlexis technology addresses these unmet challenges by simultaneously
assaying cells analyzing cell functionality at the single cell level and co detecting
effector proteins per cell This SBIR application aims to develop a suitable solution and an
alpha test prototype device by incorporating an on chip upstream cell sorting method for
capturing low quantities of circulating Tfh cells followed by a validated single cell cytokine
function profiling platform for identifying pathogenic T cells reproducibly This NIH Phase I SBIR
project will focus on developing this assay and device for lupus and autoimmune research We
propose the following specific aims develop an NACS based cell capture device for
profiling circulating Tfh cells with SCBC technology to eliminate flow sorting and
establish a single cell plex cytokine and chemokine panel specific to profiling Tfh
cells and develop the first components of an integrated automation workflow system
for capturing and analyzing single Tfh cells with required reproducibility With a validated
test system we would in Phase II apply this test to a large cohort clinical study and fully validate
this for further commercialization in a critical area for SLE patients and physicians If successful
this will open new opportunities for autoimmune disease diagnosis and monitoring of other T cell
cytokine mediated diseases Pathogenic T cells presenting in circulation play an important role in autoimmune diseases We
propose to create an automated prototype microdevice that allows for capturing specific T
helper cells from patient blood samples i e SLE patient and analyzing the cytokine
polyfunctionality of these cells at the single cell level which will be used as an early stage
biomarker to detect SLE and monitor SLE patient upon treatment This technique has the
potential to be scaled up and delivered to a broader range of autoimmune diseases and
applicable to hospital disease diagnosis pharmaceutical drug development and clinical
treatment monitoring
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
17 SBIR/STTR records share this UEI (2015–2020). Reported award amounts total $18,897,114. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards